Gong J, Chen D, Kashiwaba M, Kufe D
Division of Cancer Pharmacology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA.
Nat Med. 1997 May;3(5):558-61. doi: 10.1038/nm0597-558.
Dendritic cells (DCs) are potent antigen-presenting cells that prime naive cytotoxic T-cells (CTLs). In this study, we have fused DCs with MC38 carcinoma cells. The fusion cells were positive for major histocompatibility (MHC) class I and II, costimulating molecules and intercellular cell adhesion molecule-1 (ICAM-1). The results show that the fusion cells stimulate naive T cells in the primary mixed lymphocyte reaction (MLR) and induce MC38 tumor-specific CTLs in vivo. Antibody-mediated depletion experiments demonstrate that induction of CD4+ and CD8+ CTLs protects against challenge with tumor cells. We also show that immunization with the fusion cells induces rejection of established metastases. These findings represent the first demonstration that fusions of DCs and tumor cells can be used in the treatment of cancer.
树突状细胞(DCs)是强效的抗原呈递细胞,可启动初始细胞毒性T细胞(CTLs)。在本研究中,我们将DCs与MC38癌细胞进行了融合。融合细胞的主要组织相容性复合体(MHC)I类和II类、共刺激分子以及细胞间细胞黏附分子-1(ICAM-1)呈阳性。结果表明,融合细胞在初次混合淋巴细胞反应(MLR)中刺激初始T细胞,并在体内诱导产生MC38肿瘤特异性CTLs。抗体介导的清除实验表明,诱导CD4+和CD8+ CTLs可抵御肿瘤细胞的攻击。我们还表明,用融合细胞进行免疫可诱导已形成的转移灶发生排斥反应。这些发现首次证明DCs与肿瘤细胞的融合可用于癌症治疗。